Amsterdam Hosts ESC 2023 After Yielding to COVID in 2020

Lively and historic Amsterdam’s forthcoming turn as host to the European Society of Cardiology (ESC) Congress 2023 should go a long way toward righting at least one of the pandemic’s countless wrongs.

The city was most recently on annual meeting’s rotation in 2020, but ultimately missed out in the year SARS-CoV-2 upended the world and forced the largest medical conferences out of convention halls and into cyberspace.

But ESC-2023 will offer both options as it fills Amsterdam’s RAI Exhibition and Congress Centre on August 25 to 28 with a panoply of sessions, 106 of them livestreamed, on the latest cardiology research, controversies, and discussion of social and economic issues affecting clinical practice.

In addition to the meeting’s 77 oral abstract sessions and hundreds of moderated ePoster stations, five sessions will be dedicated to four new ESC clinical practice guidelines and a focused update to a prominent guideline from 2 years ago. Eleven other sessions during the meeting will illustrate and scrutinize the guidelines’ relevance to practice.

The new documents cover management of acute coronary syndromes, cardiomyopathies, endocarditis, and patients with diabetes, and, in the focused update, acute and chronic heart failure (HF). A 90-minute guidelines-overview session featuring highlights of all five documents is slated for Day 1 of the Congress.

The 18 sessions in the conference’s Great Debates series, conducted and livestreamed across the 4 days, present explorations of contemporary, sometimes divisive questions, including:

  • Whether to intervene via catheter in acute pulmonary embolism

  • Anatomical vs functional testing for diagnosing coronary disease

  • Whether the Universal Definition of Myocardial Infarction (MI) is “flawed and should be put to rest”

  • “Diuretics in heart failure — friend or foe?”

  • Whether artificial intelligence will replace cardiologists

The meeting’s Hot Line and Late-Breaking Science and Trial Update sessions will feature presentations on randomized trials, observational studies, and other research specially selected by committee for the highest-profile positions on the schedule.

All nine Hot Line presentations are to be streamed live and, per tradition, will conclude with a few minutes of panel discussion and critique from an invited discussant:

Hot Line 1, August 25

  • STEP HFpEF: Once-weekly semaglutide in people with heart failure with preserved ejection fraction and obesity 

  • NOAH-AFNET 6: Oral anticoagulation in patients with atrial high-rate episodes 

  • COP-AF: Colchicine for the prevention of perioperative atrial fibrillation (AF) after major thoracic surgery

Hot Line 2, August 26

  • Qiliqiangxin in patients with heart failure and reduced ejection fraction: The QUEST study

  • BUDAPEST CRT Upgrade: Cardiac resynchronization therapy upgrade in heart failure with right ventricular pacing — a multicenter, randomized, controlled trial 

  • HEART-FID: Ferric carboxymaltose (FCM) in heart failure with iron deficiency 

  • Effects of FCM on recurrent HF hospitalizations: An individual participant data meta-analysis

Hot Line 3, August 26

  • FIRE trial: Physiology-guided complete percutaneous coronary intervention (PCI) in older MI Patients 

  • ECLS-SHOCK: Venoarterial membrane oxygenation in cardiogenic shock 

  • STOPDAPT-3: An aspirin-free antithrombotic strategy for PCI

Hot Line 4, August 27

  • ILUMIEN IV: Optical coherence tomography (OCT) versus angiography

  • OCT-guided or angiography-guided PCI in complex bifurcation lesions. The OCTOBER trial

  • OCTIVUS: OCT vs intravascular ultrasound (IVUS)-guided PCI

  • OCT vs IVUS vs angiography guidance: A real-time updated network meta-analysis

Hot Line 5, August 27

  • ATTRibute-CM: Acoramidis (AG10) in patients with transthyretin amyloid cardiomyopathy

  • ARREST trial: Expedited transfer to a cardiac arrest center for out-of-hospital cardiac arrest 

  • ADVENT: Pulsed field ablation vs thermal ablation (radiofrequency/cryoballoon) for paroxysmal AF

Hot Line 6, August 27

  • MULTISTARS AMI: Multivessel immediate versus staged revascularization in ST-segment elevation myocardial infarction 

  • CASTLE-HTx: Catheter ablation versus medical therapy to treat AF in end-stage heart failure 

  • The FRAIL-AF randomized controlled trial

Hot Line 7, August 28

  • Extended clopidogrel monotherapy versus dual antiplatelet therapy in high-risk patients: The OPT-BIRISK trial

  • ARAMIS : Anakinra versus placebo in acute myocarditis 

  • DANPACE II — Reducing atrial pacing in sinus-node disease 

Hot Line 8, August 28

  • RED-CVD: Improving early diagnosis of cardiovascular disease in patients with type 2 diabetes and chronic obstructive pulmonary disease

  • NITRATE-CIN: Inorganic nitrate to prevent contrast-induced nephropathy after angiography for acute coronary syndrome

  • DICTATE-AHF: Early dapagliflozin Initiation in acute heart failure (AHF)

  • PUSH-AHF: Natriuresis-guided therapy in AHF 

Hot Line 9, August 28

  • RIGHT: Prolongation of anticoagulation after Primary PCI 

  • ONCO DVT Study: Optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer study 

  • Prospective meta-analysis of SGLT2 inhibitor randomized trials in COVID-19

European Society of Cardiology (ESC) Congress 2023.

Follow Steve Stiles on Twitter: @SteveStiles2. For more from theheart.org, follow us on Twitter and Facebook.

Source: Read Full Article